Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Health Catalyst (HCAT) Total Non-Current Liabilities (2018 - 2025)

Health Catalyst's Total Non-Current Liabilities history spans 8 years, with the latest figure at $256.6 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 48.02% year-over-year to $256.6 million; the TTM value through Dec 2025 reached $256.6 million, down 48.02%, while the annual FY2025 figure was $256.6 million, 48.02% down from the prior year.
  • Total Non-Current Liabilities reached $256.6 million in Q4 2025 per HCAT's latest filing, up from $255.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $514.3 million in Q1 2025 to a low of $255.2 million in Q3 2025.
  • Average Total Non-Current Liabilities over 5 years is $339.5 million, with a median of $333.8 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: surged 181.93% in 2021, then tumbled 48.02% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $309.9 million in 2021, then rose by 5.57% to $327.2 million in 2022, then grew by 2.34% to $334.8 million in 2023, then surged by 47.46% to $493.7 million in 2024, then plummeted by 48.02% to $256.6 million in 2025.
  • Per Business Quant, the three most recent readings for HCAT's Total Non-Current Liabilities are $256.6 million (Q4 2025), $255.2 million (Q3 2025), and $266.5 million (Q2 2025).